Posted by Michael Wonder on 17 May 2020
Less than a movie ticket or ‘impossible to overpay’? Experts name their price for remdesivir
15 May 2020 - Two weeks ago, the world learned that remdesivir, a treatment from Gilead Sciences, has a moderate but much-needed benefit for patients with COVID-19.
In the days since, public health experts, economists, and industry watchdogs have been mulling the next big question: How much should it cost?
Gilead has time and again downplayed the commercial potential of remdesivir, promising to ensure patients around the world will have access to it and taking steps to make sure that’s the case. But the company isn’t running a charity, meaning it will eventually charge some amount of money for the medicine.
